Moderna and Merck released Phase III results on Wednesday showing a personalized mRNA cancer vaccine reduced melanoma recurrence by 44 percent when combined with pembrolizumab. The trial enrolled 1,100 patients across 120 centers in North America and Europe.
Each vaccine encodes neoantigens identified from a patient's tumor biopsy. Manufacturing takes approximately six weeks from sequencing to injection, a logistics chain Moderna said it can scale to 50,000 courses annually by 2028.
Clinical Significance
Oncologists cautioned that the benefit appeared strongest in patients with high mutational burden. Subgroup analyses for lung and bladder cohorts remain underway. The Food and Drug Administration granted breakthrough therapy designation in May, signaling a likely priority review filing in the fourth quarter.
Cost Questions
Early pricing discussions center on six-figure courses per patient, raising access concerns for public health systems. European health technology assessment bodies requested cost-effectiveness models before national reimbursement decisions.
Competitive Field
BioNTech and Gritstone Bio pursue similar platforms. The results intensify investment in AI-driven neoantigen prediction tools that shorten design cycles.
Patient Pathway
Survivor advocacy groups welcomed data but urged transparent informed-consent materials explaining that vaccines supplement, rather than replace, established immunotherapies.
